| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
KDM4 (histone lysine demethylase 4) family. Zavondemstat selectively targets KDM4A-D with no effect on other KDM families. It is a reversible, alpha-ketoglutarate competitive pan-inhibitor. KDM4 enzymes are involved in epigenetic regulation and cancer progression.
|
|---|---|
| ln Vitro |
Zavondemstat demonstrates inhibition of KDM4 enzymes in biochemical assays. It causes S-phase cell cycle arrest and inhibits cancer cell proliferation in vitro. The compound has anticancer and antitumor activity. Detailed IC50 values have not been disclosed.
|
| ln Vivo |
Zavondemstat inhibits tumor growth and induces tumor regression in in vivo studies. It has been studied in triple-negative breast cancer models. The compound's in vivo efficacy supports its potential for cancer research. Additional in vivo studies would be needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for KDM4 inhibition are performed using recombinant KDM4 enzymes, alpha-ketoglutarate, and histone peptide substrates. Zavondemstat is incubated at varying concentrations with the enzyme and substrate. Demethylation is detected by mass spectrometry or fluorescence-based methods. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cells (e.g., cancer cell lines, including triple-negative breast cancer cells) are cultured and treated with Zavondemstat at concentrations typically ranging from 0.1–10 μM for 24–72 hours. KDM4 inhibition is assessed by measuring histone methylation levels (e.g., H3K9me3) by Western blot. Cell cycle analysis is performed by flow cytometry. Cell proliferation and viability are assessed by standard assays.
|
| Animal Protocol |
In vivo animal studies for Zavondemstat have been conducted in xenograft models of cancer, including triple-negative breast cancer. The compound is administered orally or intraperitoneally at doses typically ranging from 1–50 mg/kg. Tumor growth inhibition, tumor regression, and survival are evaluated. Standard protocols for KDM4 inhibitor studies in mice are used.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Zavondemstat have not been extensively published. The compound has a molecular weight of 419.48 and formula C25H29N5O2. In vivo PK parameters such as half-life, bioavailability, and tissue distribution have not been fully characterized. For in vivo use, formulation would need to be developed.
|
| Toxicity/Toxicokinetics |
Toxicology data for Zavondemstat are limited to preclinical studies. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been published. Standard safety precautions for handling chemical inhibitors should be observed.
|
| References | |
| Additional Infomation |
Zavondemstat (CAS: 1851412-93-5, molecular formula C25H29N5O2, molecular weight 419.48) is a KDM4 pan-inhibitor. It selectively targets KDM4A-D. It causes S-phase cell cycle arrest and inhibits tumor growth. It is not in clinical trials and has no regulatory approval. The compound is supplied as a research-grade inhibitor for laboratory use only.
|
| Molecular Formula |
C26H29N3O3
|
|---|---|
| Molecular Weight |
431.53
|
| Exact Mass |
431.22
|
| CAS # |
1851412-93-5
|
| Related CAS # |
1851412-93-5 (free acid);2908753-08-0 (potassium);2908753-07-9 (sodium);
|
| PubChem CID |
118597685
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
607
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)C1=CC=C(C=C1)N(C)C2=CC3=C(C=C2)[C@@H](CCO3)CNC4=C(C=CN=C4)C(=O)O
|
| InChi Key |
NDVITLLKZQXKGU-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C26H29N3O3/c1-17(2)18-4-6-20(7-5-18)29(3)21-8-9-22-19(11-13-32-25(22)14-21)15-28-24-16-27-12-10-23(24)26(30)31/h4-10,12,14,16-17,19,28H,11,13,15H2,1-3H3,(H,30,31)/t19-/m0/s1
|
| Chemical Name |
3-[[(4R)-7-(N-methyl-4-propan-2-ylanilino)-3,4-dihydro-2H-chromen-4-yl]methylamino]pyridine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3173 mL | 11.5867 mL | 23.1734 mL | |
| 5 mM | 0.4635 mL | 2.3173 mL | 4.6347 mL | |
| 10 mM | 0.2317 mL | 1.1587 mL | 2.3173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
